These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32954754)

  • 21. The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
    Zhang K; Tian M; Zeng Y; Wang L; Luo S; Xia W; Zhang X; Zha Y
    Complement Ther Med; 2020 Aug; 52():102473. PubMed ID: 32951723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
    Aouba A; Baldolli A; Geffray L; Verdon R; Bergot E; Martin-Silva N; Justet A
    Ann Rheum Dis; 2020 Oct; 79(10):1381-1382. PubMed ID: 32376597
    [No Abstract]   [Full Text] [Related]  

  • 23. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
    Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
    Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
    Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
    Chen L; Liu HG; Liu W; Liu J; Liu K; Shang J; Deng Y; Wei S
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):203-208. PubMed ID: 32164089
    [No Abstract]   [Full Text] [Related]  

  • 29. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
    Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
    Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Risk Factors for 24 Patients With COVID-19 Developing From Moderate to Severe Condition.
    Li D; Liu C; Liu J; Hu J; Yang Y; Zhou Y
    Front Cell Infect Microbiol; 2020; 10():548582. PubMed ID: 33042873
    [No Abstract]   [Full Text] [Related]  

  • 31. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the novel coronavirus disease in Turkish children: Preliminary outcomes.
    Yılmaz K; Gozupirinççioğlu A; Aktar F; Akın A; Karabel M; Yolbas I; Uzel VH; Şen V
    Pediatr Pulmonol; 2020 Dec; 55(12):3587-3594. PubMed ID: 32991038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cohort study of chest CT and clinical changes in 29 patients with coronavirus disease 2019 (COVID-19).
    Zhou Y; Zheng Y; Yang Q; Hu L; Liao J; Li X
    Eur Radiol; 2020 Nov; 30(11):6213-6220. PubMed ID: 32591890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.
    Huang Q; Deng X; Li Y; Sun X; Chen Q; Xie M; Liu S; Qu H; Liu S; Wang L; He G; Gong Z
    Int J Clin Pharm; 2020 Jun; 42(3):837-845. PubMed ID: 32410206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.
    Zhang J; Hao Y; Ou W; Ming F; Liang G; Qian Y; Cai Q; Dong S; Hu S; Wang W; Wei S
    J Transl Med; 2020 Oct; 18(1):406. PubMed ID: 33121497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2.
    Xu YH; Dong JH; An WM; Lv XY; Yin XP; Zhang JZ; Dong L; Ma X; Zhang HJ; Gao BL
    J Infect; 2020 Apr; 80(4):394-400. PubMed ID: 32109443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.